Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors

Frequent and Focal <i>FGFR1</i> Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

Jonathan M. Weiss, Martin L. Sos, Danila Seidel et al. · Science Translational Medicine · 2010 · 825 citations

Medicine, Cancer Biology, Oncology +14

<i>FGFR1</i> Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

Nicholas C. Turner, Alex Pearson, Rachel Sharpe et al. · Cancer Research · 2010 · 738 citations · Full text

Medicine, Cancer Biology, Oncology +17

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima et al. · Vascular Cell · 2014 · 500 citations · Full text

Medicine, Oncology, Pharmacology +16

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 499 citations

Medicine, Oncology, Pharmacology +16

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 489 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14